Clinical Trial Search

Primary: The Percent of Subjects Meeting Treatment Response Criteria at Week 48 According to a Combined Response Index — 33.5; 34.1; 35.2 Percentage of responders — p==0.899

Primary: The Percent of Subjects Meeting Treatment Response Criteria at Week 48 According to a Combined Response Index — 34.1; 39.8; 37.5 percentage of participants — p==0.175

Primary: Difference in the Exponential Rate of Change in Serum Potassium (S-K) Levels Versus Placebo During the Initial 48 Hours of Study Drug Treatment — 0; -0.00035; -0.00169…

Primary: Positioning Effectiveness as Determined by Confirmatory Measurements of Robotic Movements — 0.489 millimeters

Primary: Incidence of Intra-Operative Hemostatic Intervention — 0.0533; 0.0833 Proportion transections w/ intervention

Primary: Mean Difference in Change in Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) Score at Baseline and 6 Weeks. — -0.9; -5.78; 3.52; -7.26 Units on a scale

Primary: Probability of Accurately Recalling Visual Stimuli — .52; .50; .54 probability

Primary: Percentage of Participants With Successful Self-administration of Their Observed Third Dose at Week 8 - Autoinjector With Standard Label + Pictogram — 99 Percentage of…

Primary: Lovastatin AUC in the Presence of Fluoxetine — 170; 180 nmol*hr/L — p=>0.05

Primary: The Average Number of Fitting Modifications to Optimize Vision — 0.30 Lens

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 — -1.04; -1.10 Percentage of glycosylated hemoglobin — p=<0.0001

Primary: Neurocognitive Function as Measured by Performance on Standardized Tests of Attention, Memory, and Executive Function. — 0.35; 0.18; 0.06; 0.37 Z-score

Primary: Percentage of Women Who Achieve Anemia Correction After a Single Dose of 1000mg of Low Molecular Weight Iron Dextran(INfeD). — 35; 11 Participants

Primary: Pain Assessment: Overall — 15.3; 19.0 units on a scale

Primary: Mindful Attention and Awareness Scale (MAAS) — 3.79; 3.66; 1.71; 1.56 units on a scale